Literature DB >> 19355828

Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies.

Thomas Lincke1, Joerg Singer, Regine Kluge, Osama Sabri, Ralf Paschke.   

Abstract

BACKGROUND: Recent data suggest that increased somatostatin receptor (SSTR) expression is detectable in several thyroid diseases. This raises the question as to the specificity and pathophysiologic relevance of these findings. Therefore, we systematically evaluated Indium-111 (In-111) pentetreotide scintigraphies and Gallium-68 (Ga-68) DOTA-Phe(1)-Tyr(3)-Octreotide (DOTATOC) positron emission tomography (PET) scans for thyroid radiotracer uptake.
METHODS: Relative binding of In-111 pentetreotide in the thyroid was measured by region of interest (ROI) technique in 4-hour and 24-hour post-injection (p.i.) planar images of 73 patients undergoing In-111 pentetreotide scintigraphy. Ga-68 DOTATOC PET scans of 77 patients were analyzed by ROI technique applied to coronal slices of 1 cm (0.39 inch) thickness with highest uptake in the thyroid region.
RESULTS: A basal indium In-111 and Ga-68 DOTATOC uptake was found in normal thyroid glands. Hot nodules, disseminated thyroid autonomy, and most cases of active Hashimoto's disease as well as goiters and nodular thyroids showed increased In-111 pentetreotide and/or Ga-68 DOTATOC uptake. Higher relative In-111 pentetreotide uptake in the 24-hour p.i. images as compared to the 4-hour p.i. images except for patients after thyroidectomy indicates specific receptor binding in the thyroid.
CONCLUSIONS: The increased In-111 pentetreotide and Ga-68 DOTATOC uptake in active Hashimoto's disease is most likely related to the lymphocytic infiltration of the thyroid. However, the physiologic or pathophysiologic relevance of the increased In-111 pentetreotide and Ga-68 DOTATOC uptake in normal thyroid glands, hot and cold nodules, and goiters and nodular thyroids remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355828     DOI: 10.1089/thy.2008.0389

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  10 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  Somatostatin receptor expression in non-classical locations - clinical relevance?

Authors:  Eldrin Bhanat; Christian A Koch; Rinkuben Parmar; Vishnu Garla; Vani Vijayakumar
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

3.  Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.

Authors:  Hendra Budiawan; Ali Salavati; Harshad R Kulkarni; Richard P Baum
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

4.  68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax.

Authors:  Christian Boy; Till A Heusner; Thorsten D Poeppel; Anja Redmann-Bischofs; Nicole Unger; Walter Jentzen; Wolfgang Brandau; Klaus Mann; Gerald Antoch; Andreas Bockisch; Stephan Petersenn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-03       Impact factor: 9.236

Review 5.  Peptide Receptor Radionuclide Therapy in Thyroid Cancer.

Authors:  Sriram Gubbi; Christian A Koch; Joanna Klubo-Gwiezdzinska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-30       Impact factor: 6.055

Review 6.  Clinical applications of Gallium-68.

Authors:  Sangeeta Ray Banerjee; Martin G Pomper
Journal:  Appl Radiat Isot       Date:  2013-02-20       Impact factor: 1.513

Review 7.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

Review 8.  Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.

Authors:  Irina Velikyan
Journal:  Contrast Media Mol Imaging       Date:  2018-01-04       Impact factor: 3.161

9.  Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review.

Authors:  Luz Kelly Anzola; Andor W J M Glaudemans; Rudi A J O Dierckx; F Andres Martinez; Sergio Moreno; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-28       Impact factor: 9.236

10.  Octreotide uptake in parathyroid adenoma.

Authors:  Seyhan Karaçavuş; Mustafa Kula; Züleyha Cihan Karaca; Kürşad Unlühızarcı; Ahmet Tutuş; Fahri Bayram; Ganime Coban
Journal:  Mol Imaging Radionucl Ther       Date:  2012-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.